Atovaquone for salvage treatment and suppression of toxoplasmic encephalitis in patients with AIDS

Clinical Infectious Diseases

Volumn 24, Issue 3, 1997, Pages 422-429

  Torres, Ramón A ^a   Weinberg, Winkler ^b   Stansell, John ^b   Leoung, Gifford ^b   Kovacs, Joseph ^b   Rogers, Michael ^b   Scott, Janna ^b  

^a ST VINCENT S HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATOVAQUONE; CLINDAMYCIN; PYRIMETHAMINE; SULFADIAZINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; ENCEPHALITIS; FEMALE; FEVER; HEPATOMEGALY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SURVIVAL RATE; TOXIC EPIDERMAL NECROLYSIS; TOXOPLASMA GONDII; TOXOPLASMOSIS; TREATMENT OUTCOME;

EID: 20644460142     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.3.422     Document Type: Article

References (18)

1. Luft BJ, Remington JS. Toxoplasmic encephalitis. J Infect Dis 1988;157: 1-6.
2. Porter SB, Sande MA. Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome. N Engl J Med 1992;327: 1643-8.
3. Leport C, Raffi F, Matheron S, et al. Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome: efficacy of long-term continuous therapy. Am J Med 1988;84:94-100.
4. Haverkos HW. Assessment of therapy of toxoplasma encephalitis: the TE Study Group. Am J Med 1987;82:907-14.
5. Sahai J, Heimberger T, Collins K, Kaplowitz L, Polk R. Sulfadiazine-induced crystalluria in a patient with the acquired immunodeficiency, syndrome: a reminder [letter]. Am J Med 1988;84:791-2.
6. Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med 1992;116:33-43.
7. Katlama C. Evaluation of the efficacy and safety of clindamycin plus pyrimethamine for induction and maintenance therapy of toxoplasmic encephalitis in AIDS. Eur J Clin Microbiol Infect Dis 1991;10: 189-91.
8. Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1993;329:995-1000.
9. Kovacs JA, NIAID-Clinical Center Intramural AIDS Program. Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. Lancet 1992;340:637-8.
10. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566c80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993;328: 1521-7.
11. Dohn MN, Weinberg WG, Torres RA, et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med 1994;121:174-80.
12. Araujo FG, Lin T, Remington JS. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine. J Infect Dis 1993;167:494-7.
13. Kovacs JA, Polis MA, Baird B, et al. Evaluation of azithromycin or the combination of 566C80 and pyrimethamine in the treatment of toxoplasmosis [abstract no PoB 3199]. In: Program and abstracts of the 8th International Conference on AIDS (Amsterdam). Amsterdam: CONGREX Holland BV, 1992.
14. Comley JCW, Sterling AM. Synergistic effect of rifabutin on the prophylactic activity of atovaquone against Pneumocystis carinii pneumonia (PCP) in the SCID mouse [abstract no 296]. In: Program and abstracts of the 2nd National Conference on Human Retroviruses and Related Infections (Washington, DC). Washington, DC: American Society for Microbiology, 1995.
15. Lacassin F, Leport C, Schaffo P, et al. Clarithromycin-minocycline (clamino) combination therapy for toxoplasmosis (TX) in 8 AIDS patients, [abstract no 1173]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, Florida). Washington, DC: American Society for Microbiology, 1994.
16. Lopez JS, de Smet MD, Masur H, Mueller BU, Pizzo PA, Nussenblatt RB. Orally administered 566c80 for treatment of ocular toxoplasmosis in a patient with the acquired immunodeficiency syndrome [letter]. Am J Ophthalmol 1992;113:331-3.
17. Sheppard JD, Blick G, Caldwell PT, et al. Treatment of ocular toxoplasmosis with atovaquone, a cysticidal hydroxynaphthoquinone [abstract]. In: Program and abstracts of the annual meeting of the Association for Research in Vision and Ophthalmology, 1993.
18. Falloon J, Follansbee S, Reves R, et al. Atovaquone suspension for Pneumocystis carinii pneumonia (PCP) [abstract no 298]. In: Program and abstracts of the 2nd National Conference on Human Retroviruses and Related Infections (Washington, DC). Washington, DC: American Society for Microbiology, 1995.